A02
Function and targeting of membrane-bound E3 ligases in AML
Project Summary
Despite the addition of personalized medicine drugs, such as tyrosine kinase inhibitors (TKI) and others, to standard chemotherapy regimens, overall 5-year-survival rates in acute myeloid leukemia (AML) remain low at 30-40%. Especially in elderly patients survival rates are poor. The membrane proteome plays an important role in leukemia progression and aids the escape of cancer cells from various therapies. The membrane proteome of the cell is effectively regulated by certain membrane-associated E3 ubiquitin ligases. Using sophisticated technologies we will validate the function of these E3 ligases and develop novel agents targeting these proteins. Our work will allow functional insights into the role of these E3 ligases in AML, and we anticipate that this study will open up paths for novel therapies targeting membrane proteins.
